Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease

被引:14
|
作者
Cui, Jing [1 ]
Zhao, Panxiong [2 ]
Ren, Zhentai [3 ]
Liu, Baoping [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Nucl Med, Zhengzhou, Henan, Peoples R China
[2] Henan Univ, Affiliated Hosp 1, Dept Nucl Med, Kaifeng, Henan, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 5, Dept Radiat Oncol, Zhengzhou, Henan, Peoples R China
关键词
F-18-FDG PET; FDG-PET; CANCER; INDEX;
D O I
10.1097/MD.0000000000001356
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To assess the clinical value of dual time point imaging (DTPI) fluorine-18fludeoxyglucose (18F-FDG) positron emission tomography (PET)/CT in differentiating malignancy and benign disease of patients with focally increased gastric uptake.Patients who present focally increased 18F-FDG uptake in gastric wall on conventional PET/CT imaging received delayed imaging. PET/CT scans were acquired at 1 and 2hours (early and delayed imaging) after 18F-FDG injection. The maximum standardized uptake value (SUV) was calculated. The SUVmax of the early and delayed imaging acquisition were signed S1 and S2, respectively. The receiver operating characteristic curve (ROC) of the S1, S2, and the retention index (RI) were drawn to find the best cut-off point value for differential diagnosis. Sensitivity, specificity, Youden index, and the area under the curve (AUC) were calculated, respectively.From September 2010 to May 2015, 74 patients (56 male and 18 female; age of 5712 years; range, 32-86 years) referring for areas of focally increased uptake of 18F-FDG in gastric wall received delayed imaging. The S1 was 5.0 +/- 1.4 (range, 1.9-11.3), and S2 was 5.9 +/- 2.7 (range, 1.0-16.3). The SUVmax were increased in 52 patients in delayed imaging, with 85% (44/52 cases) appeared malignant; decreased in 20 patients, and 90% (18/20 cases) were benign; 2 patients of benign had not changed. The change of SUVmax between malignant and benign was significant difference (t=-5.785, P=0.000).Taking the S1, S2, and RI higher than 4.6%, 5.1%, and 13% as positive diagnostic criteria, the sensitivity were 65.2%,87.0%, and 87.0%, respectively; the specificity were 64.3%, 82.1%, and 89.3%; the Youden index were 0.332, 0.693, and 0.770; AUC were 0.635 (95% confidence intervals (95% CI) 0.507-0.764), 0.873 (95% CI, 0.786-0.961), and 0.923 (95% CI, 0.854-0.992).DTPI is more precise to distinct malignant from benign gastric diseases compared with conventional imaging, and it is readily accessible.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy
    Lin, Frank I.
    Rao, Jyotsna E.
    Mittra, Erik S.
    Nallapareddy, Kavitha
    Chengapa, Alka
    Dick, David W.
    Gambhir, Sanjiv Sam
    Iagaru, Andrei
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (02) : 262 - 270
  • [42] Benign Thoracic Lesions and Disorders: 18F-FDG PET/CT imaging
    Nguyen, B.
    Ram, P.
    Roarke, M.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2012, 198 (05)
  • [43] Dual-Time-Point 18F-FDG PET/CT Imaging in the Assessment of Advanced Colorectal Neoplasms in Patients with Focal Colorectal 18F-FDG Uptake
    Ma, Y.
    Zhou, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S517 - S517
  • [44] Dual-time point 18F-FDG PET/CT scan: is it always working?
    Farghaly, H. R. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S476 - S477
  • [45] Dual time point 18F-FDG PET/CT in patients on suspicion of malignant lymphoma
    Nielsen, Anne
    Mylam, Karen
    Pedersen, Lars
    Alavi, Abass
    Gerke, Oke
    Braad, Poul-Erik
    Hutchings, Martin
    Petersen, Henrik
    Hoilund-Carlsen, Poul
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [46] Evaluation of Malignancy Risk in 18F-FDG PET/CT Thyroid Incidentalomas
    Larg, Maria-Iulia
    Apostu, Dragos
    Pestean, Claudiu
    Gabora, Katalin
    Badulescu, Iulian Claudiu
    Olariu, Elena
    Piciu, Doina
    DIAGNOSTICS, 2019, 9 (03)
  • [47] Prospective evaluation of dual time 18F-FDG PET-CT for differentiating benign and malignant pancreatic masses: comparison with contrast enhanced CT and endoscopic ultrasound
    Kumar, R.
    Sharma, P.
    Garg, P.
    Sharma, R.
    Singla, S.
    Thulkar, S.
    Malhotra, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S582 - S582
  • [48] Dual time point imaging using 18F-FDG PET/CT in primary brain tumors - A pilot study
    Jora, Charu
    Jacob, Mattakarottu
    Chauhan, Mahesh
    Pandit, Aniruddha
    Ravina, Mudalsha
    Jain, Anurag
    Alavi, Abass
    Saboury, Babak
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [49] Gastric Carcinosarcoma and 18F-FDG PET/CT
    Li, Beilei
    Zhang, Yiqiu
    Hou, Jun
    Cai, Liang
    Zhou, Jianwei
    Shi, Hongcheng
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) : e506 - e507
  • [50] Evaluation of 18F-FDG uptake in gastric cancers using FDG PET/CT
    Koyama, K.
    Okamura, T.
    Seura, H.
    Hamazawa, Y.
    Miki, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S373 - S373